Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review.

Peter GalleRichard S FinnCatherine Ruth MitchellKerigo NdiranguZahra RamjiGabrielle Sophie RedheadDavid James Pinato

Published in: Journal for immunotherapy of cancer (2024)

Checkpoint inhibitors for the treatment of cancer are immunogenic, with the incidence of treatment-emergent ADAs varying between individual therapies. It remains unclear what impact ADAs have on treatment outcomes.

Keyphrases

risk factors
young adults
childhood cancer